Treatment of adrenal metastases with conventional or hypofractionated image-guided radiation therapy

• Verfasst von: Bürgy, Daniel [VerfasserIn]
• Verfasst von: Rabe, Leonie [VerfasserIn]
• Verfasst von: Siebenlist, Kerstin [VerfasserIn]
• Verfasst von: Stieler, Florian [VerfasserIn]
• Verfasst von: Fleckenstein, Jens [VerfasserIn]
• Verfasst von: Giordano, Frank Anton [VerfasserIn]
• Verfasst von: Wenz, Frederik [VerfasserIn]
• Verfasst von: Boda-Heggemann, Judit [VerfasserIn]
• Titel: Treatment of adrenal metastases with conventional or hypofractionated image-guided radiation therapy
• Titelzusatz: patterns and outcomes
• Verf.angabe: Daniel Buergy, Leonie Rabe, Kerstin Siebenlist, Florian Stieler, Jens Fleckenstein, Frank A. Giordano, Frederik Wenz and Judit Boda-Heggemann
• Jahr: 2018
• Umfang: 8 S.
• Teil: volume:38
• Teil: year:2018
• Teil: number:8
• Teil: pages:4789-4796
• Teil: extent:8
• Fussnoten: Gesehen am 24.10.2019
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Attiki, 2004
• Jahr Quelle: 2018
• Band/Heft Quelle: 38(2018), 8, Seite 4789-4796
• ISSN Quelle: 1791-7530
• DOI: doi:10.21873/anticanres.12788
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adrenal metastases
• Sach-SW: oligometastases
• Sach-SW: oligoprogression
• Sach-SW: radiation therapy
• Sach-SW: SBRT
• K10plus-PPN: 1679769375

Abstract

Background/Aim: Metastases involving the adrenal glands can be treated surgically or with radiation therapy. Retrospective studies indicate that radiotherapy for this indication is safe, well-tolerated and associated with symptom palliation and good local control. We conducted this analysis to report on patterns and outcomes of patients with adrenal metastases treated with hypo- or conventionally fractionated image-guided radiotherapy. Patients and Methods: Patients with adrenal metastases from solid tumors treated at our department between 01/2010-12/2017 were reviewed. A total of 22 lesions were treated in 18 patients with a median dose of 35 Gy (20-60 Gy) in a median number of 7 (4-25) fractions. Results: No grade ≥3 toxicity occurred. Median overall survival was 11.9 months. Five local failures occurred (22.7%). Lesion sizes or radiation dose were not correlated with local control. Patients treated for oligometastatic and oligoprogressive disease had a median overall survival of 33 and 6.5 months, respectively (palliative/polymetastatic: 1.6 months). Symptoms improved in all patients treated for clinically apparent lesions. Conclusion: Stereotactic radiotherapy of adrenal metastases was safe and effective in patients with oligometastases or oligoprogression. In palliative patients, short-course radiotherapy complemented with supportive care should be preferred.